MDMA & THE MANAGEMENT OF CHRONIC PAIN

White Paper

Cliff Dominy PhD

TABLE OF CONTENTS



Executive Summary

Chronic pain affects over 1.5 billion people globally, and is a major contributor to disability, and reduced quality of life. Prolonged opioid-based therapies come with an increased risk of addiction. A non-opioid, non-addictive analgesic is needed to circumvent the short-comings of opioid therapy in a multibillion dollar market [1].

Research has focused on modifying 3,4-methylenedioxymethamphetamine (MDMA), street-name Ecstasy, to address the problem. Scientists aim to leverage its unique neurochemical properties, whilst modifying its addictive side effects - to repurpose MDMA as a safe and effective pain management option in humans.

Animal studies have shown promise with sub-psychedelic doses of MDMA appearing effective in the management of both inflammatory and neuropathic pain in mice [2]. MDMA boosts both serotonin and oxytocin in the animals whilst simultaneously lowering the inflammatory markers TNFa and IL-1B. These mice do not display overt hallucinogenic behaviours suggesting that there might be a therapeutic window for using native MDMA itself as a treatment option.

Research has only just begun and clinical evidence is currently limited. The US Food and Drug Administration has not yet approved MDMA for any clinical use. However, phase 3 trials are underway examining its safety and efficacy in treating post-traumatic stress disorder (PTSD) in conjunction with psychotherapy [3]. Preliminary results suggest that trial participants reported a reduction in chronic pain symptoms - an encouraging sign.

Research is in its infancy and investment opportunities to get in, on the ground floor, abound.

Current research priorities include …

1. At the preclinical research phase, there remains a need to produce a non-psychedelic variant of MDMA which is both safe and effective in managing chronic pain.
2. Clinical research should prioritize Phase II proof-of-concept trials for neuropathic and musculoskeletal pain which incorporate objective pain biomarkers, to validate MDMA's role as a novel non-opioid analgesic.

Introduction

The original synthesis of MDMA (3,4-methylenedioxymethamphetamine), or Ecstacy, was described by Merck in 1912 for use as an appetite suppressant[4]. By the 1970's psychotherapists were studying MDMA as an empathogen due to its ability to foster emotional openness during the processing of trauma.

MDMAs clinical utility was short-lived however, when in 1985 recreational abuse earned it a schedule 1 classification under the Controlled Substances Act. By the early 2000s, the Multidisciplinary Association for Psychedelic Studies (MAPS) received FDA approval for pilot trials in chronic, treatment-resistant post-traumatic stress disorder (PTSD) [3]. These studies showed that MDMA-assisted psychotherapy produced significant and sustained reductions in PTSD severity, with an acceptable safety profile and no serious adverse events. In 2017 the FDA gave MDMA a Breakthrough Therapy Designation, which sped up Phase III trials.

Animal studies have shown that MDMA has the unusual ability to elevate synaptic serotonin, dopamine and norepinephrine and to trigger oxytocin release [5]. This combined hormonal effect eliminates fear in mice, possibly by enhancing synaptic plasticity in the amygdala and the prefrontal cortex which may disrupt the reconsolidation of traumatic memories.

Beyond its effects on fear circuitry, MDMA has shown promise as an analgesic in rodent models of chronic pain [2]. MDMA-treated animals show decreases in neuropathic pain and heat sensitivity correlating with the suppression of spinal nerve transmission and reduced proinflammatory cytokines. The research showed oxytocin release with sub-psychedelic doses of MDMA. This is important, as these effects occur at doses below psychoactive thresholds, suggesting a therapeutic window for non-hallucinogenic pain relief.

In 2025, MDMA use is limited to research settings under stringent study protocols and administered by qualified psychotherapists. With this environment, the development of a non-hallucinogenic MDMA variant is critical to the broader acceptance of the drug in other clinical settings.

The social side-effects of MDMA abuse extend beyond the "high". Several other challenges need to be addressed by clinical trials. Regulatory authorities are demanding long-term safety data, particularly regarding neurotoxicity and cardiotoxicity, which remain incompletely characterized. The stigma of Ecstasy has limited funding opportunities in the field and may well be an obstacle to patient enrolment in the broader population.

In summary, MDMA has travelled a tumultuous path since 1912. However its therapeutic value is promising and its potential to reduce human suffering enormous. MDMA and its derivatives deserve another look.

Properties of MDMA

Chemically, MDMA (3,4-methylenedioxy-methamphetamine) is a mildly hallucinogenic member of the amphetamine family. Its physical and chemical properties are listed in Table 1.

It is a hydrophobic ion and, in order to improve its solubility in water, it is synthesized as a chloride or phosphate salt. It exists in two forms - the R and S enantiomers.



Image : American Chemical Society

Table 1: Chemical & Physical Properties of MDMA

IUPAC Name	(RS)-1-(1.3-Benzodioxol-5-yl)-N-methylpropan-2-amine
Molecular Formula	$C_{11}H_{15}NO_2$
Molar Mass	193.25 g/mol
CAS Number	42542-10-9
Chirality	Recemic mixture (R- and S-enantiomerr)
Chemical Class	Substituted amphetamine / phenethylamine
Physical Traits	White/off-white crystalline powder (hydrochloride salt)
Appearance	147-153°C (HCl); 184-185°C (phosphate)
Boiling Point	~105°C at 0.4 mmHg
Density	~1.1 g/cm^3
Solubility	Moderate in water: high in ethanol, methanol, chloroform
Odor	Odorless in pure form
Taste	Bitter

Table 2: Pharmacokinetics & Analytical Features of MDMA

Pharmacokinetics	30–45 minutes (oraal)
Onset of Action	30–45 minutes (oral)
Duration	3–6 hours
Half-Life	~8.7 hours (range: 4.6–16 hours)
Bioavailability	Not precisely established
Major Metabolites	MDA, HMMA, HMA
Excretion	Renal: mostly unchanged

R-MDMA is of greater interest to the pharmaceutical industry, as it provides a better empathogenic response with fewer side effects at higher doses compared with S-MDMA.

The R forms' improved safety profile and longer half-life (14 hrs) is due to its binding to a different serotonin receptor variant (5-HT_2C).

The S-form has a greater affinity for the 5-HT_2A serotonin receptor, is more hallucinogenic (Table 2) and has a shorter half-life of 4 hours.



Mechanism of Action

Native MDMA exerts its psychoactive effects by upregulating the 5-HT_2A serotonin receptor[6]. Unlike more potent hallucinogens (LSD, psylocibin etc) which bind to the serotonin receptor directly, MDMA increases serotonin production itself. This indirect activation of the receptor explains why MDMAs sensory “experience” is strongly dose-dependent and allows for a therapeutic window to be developed to better leverage MDMAs pain management benefits whilst minimising its hallucinogenic side effects.

High doses of MDMA are profoundly neurotoxic and proinflammatory [7]. The drug causes an imbalance in several neurological pathways …

- Serotonin: MDMA has a high binding affinity for the serotonin transporter (SERT). At higher concentrations it reverses the transporter thus inhibiting reuptake of the hormone in the brain. This results in prolonged euphoria, heightened sensory perception, increased sociability, and empathy.
- Dopamine and Glutamate: Dopamine is also released in the hippocampus, which raises glutamate. Glutamate over stimulates the neurotransmitters in the hippocampus causing excitotoxicity - neuronal damage.
- GABA: Higher doses of MDMA alter gamma amino butyric acid (GABA) signalling. GABA is the brains primary neurotransmitter and plays a critical role in long term memory function.
- Oxidative Stress: MDMA increases the production of free radicals (reactive oxygen species), which inhibit mitochondrial function, leading to energy deficits and neuronal death.
- Cognitive Impairment: MDMA abuse impairs memory and learning in humans. This is primarily because of hippocampal dysfunction and dopaminergic receptor signaling.

The Field

Several clinical trials registered on ClinicalTrials.gov are investigating the safety and efficacy of MDMA in treating post-traumatic stress disorder (PTSD). However, as of now, no studies list chronic pain as a primary outcome. Notably, US-based researchers at have reported exploratory findings of pain relief among a subset of participants in a 2023 Phase 3 PTSD trial [3].

A new initiative from researchers at St. Michael's Hospital in Toronto, Canada, has a Phase 1 clinical trial application under review to evaluate MDMA for the treatment of chronic nerve pain. Since 2022, Health Canada has permitted limited use of MDMA in clinical research. If approved, the study is expected to be completed by 2026.

Beyond clinical trials, intellectual property filings suggest growing interest in pain-related applications:

- Shanti Therapeutics Inc. (Toorak, Australia) submitted an application in 2021 to begin Phase 2 trials investigating MDMA for the management of post-operative pain. Results are pending.

- Mind Medicine Inc. (New York, USA) filed a 2024 patent application detailing MDMA dosage regimens specifically targeting chronic pain.

Key Take-aways

The primary challenge in evaluating MDMA for chronic pain management lies in the adverse effects associated with the native molecule. Strategically modifying the compound to reduce these side effects while preserving its therapeutic potential is an essential step before advancing into clinical trials.

Such molecular modification will not only enhance the drug's safety profile but also open the door to reclassification from a Schedule I controlled substance. This shift would significantly streamline the regulatory approval pathway and reduce the social stigma surrounding the new drug - thereby fostering a broader acceptance among patients and providers within the multibillion-dollar pain management market.

References

1 Christie D, Yazar-Klosinski B, Nosova E, Kryskow P, Siu W, Lessor D and Argento E (2022) MDMA-assisted therapy is associated with a reduction in chronic pain among people with post-traumatic stress disorder. Front. Psychiatry 13:939302.

2 Rein et al. MDMA enhances empathy-like behaviors in mice via 5-HT release in the nucleus accumbens. Sci. Adv.**10**,6554(2024).

3 Mitchell, J.M., Ot'alora G., M., van der Kolk, B. *et al.* MDMA-assisted therapy for moderate to severe PTSD: a randomized, placebo-controlled phase 3 trial. *Nat Med* 29, 2473–2480 (2023).

4 O'Leary, G., Nargiso, J. & Weiss, R.D. 3,4-methylenedioxymethamphetamine (mdma): A review. Curr Psychiatry Rep 3, 477–483 (2001).

5 Alvarez MM, Vieira AC, Sichieri R, Veiga GV. Prevalence of metabolic syndrome and of its specific components among adolescents from Niterói City, Rio de Janeiro State, Brazil. Arq Bras Endocrinol Metabol. 2011;55(2):164-170.

6 Sessa B, Higbed L, Nutt D. A Review of 3,4-methylenedioxymethamphetamine (MDMA)-Assisted Psychotherapy. Front Psychiatry. 2019;10:138. Published 2019 Mar 20.

7 Burgess C, O'Donohoe A, Gill M. Agony and ecstasy: a review of MDMA effects and toxicity. *European Psychiatry*. 2000;15(5):287-294.